Dual antiplatelet therapy duration: what are the drivers?

@article{Musumeci2011DualAT,
  title={Dual antiplatelet therapy duration: what are the drivers?},
  author={Giuseppe Musumeci and Emilio Di Lorenzo and Marco Valgimigli},
  journal={Current Opinion in Cardiology},
  year={2011},
  volume={26},
  pages={S4–S14}
}
Purpose of review To address the evidence, or lack thereof, of dual antiplatelet therapy (DAPT) duration in the percutaneous coronary intervention (PCI) setting. Recent findings The most recent guidelines on DAPT in the PCI setting are rather discordant about the duration of therapy and refer to results of studies which are often controversial. We extracted the common messages shared from guidelines, and evaluated the most recent studies on DAPT duration. The European guidelines recommend a… 
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation
TLDR
Clinical guidelines and studies regarding optimal duration of DAPT are discussed and it is pointed out that to balance the benefit and risk, optimizing D APT duration is crucial.
Long-term outcomes following very late stent thrombosis of drug-eluting stent.
Very Long-Term Follow-Up After Coronary Rotational Atherectomy: A Single-Center Experience
TLDR
The results point to RA having reasonable long-term clinical results, especially in combined treatment with DES, as well as major adverse cardiac events (MACE) being defined as the composite of target vessel revascularization, acute myocardial infarction, and all-cause mortality.
Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy
TLDR
It is demonstrated that neoadjuvant imatinib therapy can be performed safely not only to downsize tumors, but also to allow adequate time for the effective treatment of major comorbid illnesses.

References

SHOWING 1-10 OF 59 REFERENCES
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
TLDR
The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes.
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
TLDR
The extended use of clopidogrel in patients with DES may be associated with a reduced risk for death and death or MI, and the appropriate duration for clopIDogrel administration can only be determined within the context of a large-scale randomized clinical trial.
Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation
TLDR
ATD during the first year after drug-eluting stent implantation is based mainly on patient decision or a medical decision not associated with major bleeding events or major surgical procedures, and individual- and hospital-level variables are important to predict ATD.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
TLDR
In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
TLDR
The 4 year incidence of ST after DES implantation is low, and a relevant number of ST occur early after discontinuation of clopidogrel therapy.
Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
TLDR
Discontinuation of both thienopyridine and aspirin, but not discontinuation of thienobyridine therapy only, was associated with an increased risk of stent thrombosis in patients undergoing sirolimus-eluting stent implantation.
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
TLDR
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
TLDR
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluted stents than with bare-metal stents, and both drug-elution stents were associated with a marked reduction in target-lesion revascularization.
...
...